These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 8765031)

  • 21. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.
    Chen L; McGowan P; Ashe S; Johnston JV; Hellström I; Hellström KE
    Cancer Res; 1994 Oct; 54(20):5420-3. PubMed ID: 7522958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice.
    Wang YC; Zhu L; McHugh R; Sell KW; Selvaraj P
    Eur J Immunol; 1995 May; 25(5):1163-7. PubMed ID: 7774619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
    Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells.
    Plumas J; Chaperot L; Jacob MC; Molens JP; Giroux C; Sotto JJ; Bensa JC
    Eur J Immunol; 1995 Dec; 25(12):3332-41. PubMed ID: 8566020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
    Leong C; Marley J; Loh S; Robinson B; Garlepp M
    Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
    Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells.
    Zheng G; Liu S; Wang P; Xu Y; Chen A
    Cancer Res; 2006 Jul; 66(13):6793-9. PubMed ID: 16818656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
    Hiroishi K; Tüting T; Tahara H; Lotze MT
    Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors.
    Zitvogel L; Robbins PD; Storkus WJ; Clarke MR; Maeurer MJ; Campbell RL; Davis CG; Tahara H; Schreiber RD; Lotze MT
    Eur J Immunol; 1996 Jun; 26(6):1335-41. PubMed ID: 8647214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costimulation of IL-4 production by murine B7-1 and B7-2 molecules.
    Natesan M; Razi-Wolf Z; Reiser H
    J Immunol; 1996 Apr; 156(8):2783-91. PubMed ID: 8609397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
    Gajewski TF; Fallarino F; Uyttenhove C; Boon T
    J Immunol; 1996 Apr; 156(8):2909-17. PubMed ID: 8609411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.
    Hodge JW; Abrams S; Schlom J; Kantor JA
    Cancer Res; 1994 Nov; 54(21):5552-5. PubMed ID: 7522961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function.
    Brunschwig EB; Levine E; Trefzer U; Tykocinski ML
    J Immunol; 1995 Dec; 155(12):5498-505. PubMed ID: 7499830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid induction of tumor necrosis factor cytotoxicity in naive splenic T cells by simultaneous CD80 (B7.1) and CD54 (ICAM-1) co-stimulation.
    Nishio M; Podack ER
    Eur J Immunol; 1996 Sep; 26(9):2160-4. PubMed ID: 8814262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.